

APPLICATIONS

Ivermectin and Related Substances: Ph. Eur. Monograph 1336

James Turner¹ and Heiko Behr²

¹Phenomenex Ltd., Melville House, Queens Ave, Hurdsfield Ind. Estate, Macclesfield, UK

²Phenomenex, Ltd., Zepelinstrasse 5, 63741 Aschaffenburg, Germany

Introduction

Ivermectin is an active substance used for the oral treatment of parasitic diseases and is a member of the avermectin group. The action of ivermectin is to bind to chloride channels, which leads to paralysis and death of the parasites. Ivermectin is a mixture of the two ivermectin components H2B1a and H2B1b. The two molecules differ structurally only by a methylene group.

The related substances test of the European Pharmacopoeia (Ph. Eur.) Monograph 1336 outlines the separation of components H2B1a and H2B1b. This method was studied, and improvements were made to provide a faster separation time whilst maintaining the resolution (RS) required in the system suitability test, at the same time remaining within the allowable adjustments laid out by the European Pharmacopoeia 10.

Ph. Eur. Monograph 1336 Details

Test Solution: Dissolve 40.0 mg of the substance to be examined in methanol R and dilute to 50.0 mL with the same solvent.

Reference Solution (a): Dissolve 40.0 mg of Ivermectin CRS* in methanol R and dilute with 50.0 mL with the same solvent.

Column:

Size: L = 250 mm, ID = 4.6 mm

Stationary Phase: Octadecylsilyl silica gel for chromatography R (5 µm)

Mobile Phase: Water R, methanol R, acetonitrile R (15:34:51 v/v/v)

Flow Rate: 1 mL/min

Detection: Spectrophotometer @ 254 nm

Injection: 20 µL

Temperature: 25 °C


Elution Order:
1. Component H2B1b
2. Component H2B1a

System Suitability: Reference Solution (a):
Resolution: Minimum 3.0 between the 1st peak (Component H2B1b) and 2nd peak (Component H2B1a)
Symmetry factor: maximum 2.5 for the principle peak in the chromatogram

* Ivermectin CRS (I8000010), batch 2.0 was purchased from European Directorate for the Quality of Medicines & HealthCare (EDQM) – Council of Europe; Postal address: 7 Allée Kastner CS 30026 F - 67081 STRASBOURG (France).

Original Method as Described in the Monograph

Reference solution (a)



Peak	Name	Retention time, min	Symmetry	Resolution
1	Component H2B1b	30.28		
2	Component H2B1a	39.54	1.1	7.4

HPLC Conditions

Column: Luna[®] 5 µm C18(2)

Dimension: 250 x 4.6 mm

Part No.: 00G-4252-EQ

HPLC System: Shimadzu Nexera XR

Mobile Phase: Water, methanol, acetonitrile (15:34:51 v/v/v)

Flow Rate: 1.0 mL/min


Injection Volume: 20 µL

Temperature: 25 °C

Detection: UV @ 254 nm

Original Method as Described in the Monograph

Test solution




Peak	Name	Retention time, min	Symmetry	Resolution
1	Component H2B1b	30.28		
2	Component H2B1a	39.57	1.1	7.5

HPLC Conditions

Column:	Luna [®] 5 μm C18(2)
Dimension:	250 x 4.6 mm
Part No.:	00G-4252-E0
HPLC System:	Shimadzu Nexera XR
Mobile Phase:	Water, methanol, acetonitrile (15:34:51 v/v/v)
Flow Rate:	1.0 mL/min
Injection Volume:	20 μL
Temperature:	25 °C
Detection:	UV @ 254 nm

Faster Method Within Allowable Adjustments

Test solution



Peak	Name	Retention time, min	Symmetry	Resolution
1	Component H2B1b	18.19		
2	Component H2B1a	23.67	1.5	7.1

HPLC Conditions

Column:	Luna [®] 3 μm C18(2)
Dimension:	150 x 4.6 mm
Part No.:	00F-4251-E0
HPLC System:	Shimadzu Nexera XR
Mobile Phase:	Water, methanol, acetonitrile (15:34:51 v/v/v)
Flow Rate:	1.0 mL/min
Injection Volume:	20 μL
Temperature:	25 °C
Detection:	UV @ 254 nm

Adjustments for Meeting System Suitability (European Pharmacopeia 9.0, Chapter 2.2.46. Chromatographic Separation Techniques)

Method Parameter	Allowed Adjustments (isocratic elution)	Method 1	Method 2
Mobile Phase pH	± 0.2 units	Not specified	No change
Concentration of Salts in Buffer	± 10 %	Not specified	No change
Composition of the Mobile Phase	± 30 % of the minor solvent component relative or 2 % absolute, whichever is the larger. No other component is altered by more than 10 % absolute.	As specified in Monograph 1336 Details Table	No change
Wavelength of Detector	no deviations permitted	254 nm (as specified)	No change
Injection Volume	May be decreased, provided detection and repeatability of the peak(s) to be determined are satisfactory.	20 µL (as specified)	
Column Temperature	± 10 °C	Ambient (as specified)	No change
Stationary Phase	No change of the identity of the substituent permitted (e.g. no replacement of C18 by C8)	octadecylsilyl silica gel for chromatography (as specified)	No change
Column Length	± 70 %	250 mm (as specified)	150 mm (- 40 %)
Column Internal Diameter	± 25 %	4.6 mm	No change
Particle Size	- 50 %	5 µm (as specified)	3 µm (- 40 %)
Flow Rate	± 50 %	1.0 mL/min (as specified)	No change

Ordering Information

3 µm MidBore™ and Analytical Columns (mm)									SecurityGuard™ Cartridges (mm)	
Phases	30 x 3.0	50 x 3.0	150 x 3.0	30 x 4.6	50 x 4.6	75 x 4.6	100 x 4.6	150 x 4.6	4 x 2.0*	4 x 3.0*
C18(2)	00A-4251-Y0	00B-4251-Y0	00F-4251-Y0	00A-4251-E0	00B-4251-E0	00C-4251-E0	00D-4251-E0	00F-4251-E0	/10pk AJ0-4286	/10pk AJ0-4287
									for ID: 2.0-3.0 mm	3.2-8.0 mm

5 µm Analytical and Semi-Prep Columns (mm)					SecurityGuard™ Cartridges (mm)	
Phases	100 x 4.6	150 x 4.6	250 x 4.6	250 x 10	4 x 3.0*	10 x 10‡
C18(2)	00D-4252-E0	00F-4252-E0	00G-4252-E0	00G-4252-N0	AJ0-4287 /10pk	AJ0-7221 /3pk
					for ID: 3.2-8.0 mm	9-16 mm

*SecurityGuard™ Analytical Cartridges require holder, Part No.: [KJ0-4282](#)
‡SemiPrep SecurityGuard™ Cartridges require holder, Part No.: [AJ0-9281](#)

APPLICATIONS

Australia

t: +61 (0)2-9428-6444
auiinfo@phenomenex.com

Austria

t: +43 (0)1-319-1301
anfrage@phenomenex.com

Belgium

t: +32 (0)2 503 4015 (French)
t: +32 (0)2 511 8666 (Dutch)
beinfo@phenomenex.com

Canada

t: +1 (800) 543-3681
info@phenomenex.com

China

t: +86 400-606-8099
cninfo@phenomenex.com

Denmark

t: +45 4824 8048
nordicinfo@phenomenex.com

Finland

t: +358 (0)9 4789 0063
nordicinfo@phenomenex.com

France

t: +33 (0)1 30 09 21 10
franceinfo@phenomenex.com

Germany

t: +49 (0)6021-58830-0
anfrage@phenomenex.com

India

t: +91 (0)40-3012 2400
indiainfo@phenomenex.com

Ireland

t: +353 (0)1 247 5405
eireinfo@phenomenex.com

Italy

t: +39 051 6327511
italiainfo@phenomenex.com

Luxembourg

t: +31 (0)30-2418700
nlinfo@phenomenex.com

Mexico

t: 01-800-844-5226
tecnicomx@phenomenex.com

The Netherlands

t: +31 (0)30-2418700
nlinfo@phenomenex.com

New Zealand

t: +64 (0)9-4780951
nzinfo@phenomenex.com

Norway

t: +47 810 02 005
nordicinfo@phenomenex.com

Poland

t: 0-0-800-4911952
pl-info@phenomenex.com

Portugal

t: +351 221 450 488
ptinfo@phenomenex.com

Singapore

t: +65 800-852-3944
sginfo@phenomenex.com

Spain

t: +34 91-413-8613
espinfo@phenomenex.com

Sweden

t: +46 (0)8 611 6950
nordicinfo@phenomenex.com

Switzerland

t: +41 (0)61 692 20 20
swissinfo@phenomenex.com

United Kingdom

t: +44 (0)1625-501367
ukinfo@phenomenex.com

USA

t: +1 (310) 212-0555
info@phenomenex.com

**☎ All other countries/regions
Corporate Office USA**

t: +1 (310) 212-0555
info@phenomenex.com

**www.phenomenex.com**

Phenomenex products are available worldwide. For the distributor in your country/region, contact Phenomenex USA, International Department at international@phenomenex.com

Terms and Conditions

Subject to Phenomenex Standard Terms & Conditions, which may be viewed at www.phenomenex.com/TermsAndConditions.

Trademarks

Luna is a registered trademark and SecurityGuard and MidBore are trademarks of Phenomenex.

Disclaimer

FOR RESEARCH USE ONLY. Not for use in clinical diagnostic procedures.

© 2019 Phenomenex, Inc. All rights reserved.